In a 73-year-old man with chronically low alkaline phosphatase (31–33 U/L), should this be a cause for concern?

Chronically Low Alkaline Phosphatase in a 73-Year-Old Man: Clinical Significance

Yes, a chronically low alkaline phosphatase (31-33 U/L) in a 73-year-old man warrants investigation, as it may signal hypophosphatasia (HPP) or other clinically significant conditions that could affect bone health, fracture risk, and treatment decisions—particularly regarding antiresorptive therapy.

Why This Matters

A persistently low ALP is not benign in older adults. Research demonstrates that 0.4% of patients have persistently low ALP levels, and among those with documented low ALP, approximately 3% have hypophosphatasia 1. More importantly, 50% of adults with unexplained low ALP carry pathogenic ALPL gene mutations 2, even when clinical manifestations appear mild.

Immediate Clinical Concerns

Risk of Misdiagnosis and Mistreatment

The most critical concern is that HPP can be mistaken for osteoporosis, leading to inappropriate treatment with bisphosphonates or other antiresorptives—therapies that are relatively contraindicated in HPP and may worsen outcomes 1. This is particularly relevant in a 73-year-old who might otherwise be considered for osteoporosis treatment.

Recognition Gap

Studies show that low ALP is recognized in only 3% of cases in clinical practice 3, meaning most patients go undiagnosed despite having a readily identifiable biochemical marker.

Diagnostic Workup Algorithm

Step 1: Confirm Persistence and Measure Substrates

• Verify ALP remains low on repeat testing (already established in this case)
• Measure serum pyridoxal phosphate (vitamin B6): Elevated levels (above reference range) strongly suggest enzyme deficiency and are found in all HPP patients with ALPL mutations 2
• Measure 24-hour urine phosphoethanolamine (PEA): Elevated levels correlate with low ALP (r=-0.49) and support HPP diagnosis 2
• Consider bone-specific ALP if total ALP is borderline, as cases exist with normal total ALP but low bone-specific ALP 4

Step 2: Clinical Assessment for HPP Features

Look specifically for 5, 1:

• Dental history: Early tooth loss, dental abscesses, periodontitis (48% of mutation carriers vs 12% without mutations) 2
• Skeletal symptoms: Bone pain, muscle weakness, stress fractures, pseudofractures
• Joint manifestations: Chondrocalcinosis, calcific periarthritis
• Fracture history: Particularly atypical femoral fractures (2/22 patients with AFF had low ALP) 1

Step 3: Exclude Secondary Causes

Rule out conditions that can lower ALP 6, 5:

• Malnutrition or calorie depletion
• Magnesium deficiency
• Hypothyroidism
• Severe anemia
• Recent cardiac surgery (though unlikely to be "chronic")
• Medications (particularly antiresorptives if already prescribed)

Step 4: Genetic Testing

If pyridoxal phosphate is elevated or clinical features suggest HPP, proceed with ALPL gene sequencing 5, 2. This confirms diagnosis and guides management, though note that some patients with biochemical evidence of enzyme deficiency may have normal exon sequencing (suggesting regulatory region mutations or epigenetic changes) 5.

Clinical Implications for Management

If HPP is Diagnosed

• Avoid bisphosphonates and denosumab: These antiresorptive agents exacerbate low bone turnover and are contraindicated 7, 1
• Consider asfotase alfa (enzyme replacement therapy) if symptomatic 4
• Monitor for fracture risk with alternative strategies

If HPP is Excluded

• Standard osteoporosis evaluation and treatment may proceed if indicated
• Continue monitoring ALP as part of routine care

Key Pitfalls to Avoid

1. Don't dismiss low ALP as clinically insignificant: The prevalence of 0.13-0.19% in hospital populations means it's rare but not negligible 3, 6

2. Don't start bisphosphonates without excluding HPP: This is the most dangerous error, as it may worsen bone disease in undiagnosed HPP patients 1

3. Don't rely solely on total ALP: Bone-specific ALP may be more sensitive in some cases 4

4. Don't assume absence of symptoms rules out HPP: Adult-onset HPP often presents with mild manifestations, and the inverse correlation between ALP and substrate accumulation (PLP, PEA) occurs even in minimally symptomatic patients 2

Bottom Line

In this 73-year-old man, measure serum pyridoxal phosphate and urine phosphoethanolamine immediately. If either is elevated, pursue genetic testing for ALPL mutations and avoid antiresorptive therapy until HPP is excluded. Even if genetic testing is negative, the persistently low ALP should influence treatment decisions, particularly regarding bone-active medications. The stakes are high: misdiagnosis could lead to harmful treatment, while correct identification enables appropriate management and prevents complications.